(29 days)
The FlexCath Steerable Sheath is intended for percutaneous catheter introduction into the vasculature and into the chambers of the heart. The Sheath deflection facilitates catheter positioning.
The FlexCath Steerable Sheath is a deflectable catheter introducer used to facilitate placement of a catheter through the skin into the artery or vein. It is comprised of the following two (2) main sections: the shaft and the handle. A dilator is included with each sheath. This application addresses changes to the 12F FlexCath sheath tip and valve assembly.
The FlexCath Steerable Sheath & Dilator (K102176) is intended for percutaneous catheter introduction into the vasculature and chambers of the heart. The sheath's deflection facilitates catheter positioning. The predicate devices are K081049 - FlexCath Steerable Sheath & Dilator, Models 3FC10, 3FC12.
1. Table of Acceptance Criteria and Reported Device Performance
| Test | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| Hemostasis valve leak testing | Per ISO 11070 | Met |
| Hub-to-shaft tensile | Per ISO 11070 | Met |
| Shaft leak testing | Per ISO 11070 | Met |
| Detachment force: dilator luer lock from sheath valve cap | Not specified | Met |
| Removal force: dilator from sheath | Not specified | Met |
| Tensile testing of bond joints (valve hub to valve cap, hub body to extension tube, stopcock to extension tube) | Not specified | Met |
| Sheath tip robustness (multiple catheter deployments/retractions) | Not specified | Met |
| Air aspiration and flushing ability | Not specified | Met |
| Tip strength | Not specified | Met |
| Deflection testing | Not specified | Met |
| Sterilization cycle impact | In accordance with AAMI TIR28:2001 | Met |
| Biocompatibility: Physicochemical testing | USP 33 <661> | Met |
| Biocompatibility: Cytotoxicity testing | ISO 10993-5 (2009) | Met |
| Biocompatibility: Hemolysis testing (human activated and indirect) | ISO 10993-4 (2002 Amd 2006) | Met |
| Biocompatibility (leveraged from predicate): Kligman Maximization Test | ISO 10993-10 (2002) | Met |
| Biocompatibility (leveraged from predicate): Rabbit Pyrogen Test | ISO 10993-11 (2006) | Met |
| Biocompatibility (leveraged from predicate): Intracutaneous Test | ISO 10993-10 (2002) | Met |
| Biocompatibility (leveraged from predicate): Systemic Injection Test | ISO 10993-11 (2006) | Met |
| Biocompatibility (leveraged from predicate): Complement Activation Assay | ISO 10993-4 (2002) | Met |
| Biocompatibility (leveraged from predicate): UPTT | ISO 10993-4 (2002) | Met |
| Biocompatibility (leveraged from predicate): Thrombogenicity In vivo canine | ISO 10993-4 (2002) | Met |
2. Sample Size Used for the Test Set and Data Provenance
The document does not explicitly state specific sample sizes for each test in the test set. However, it mentions "representative finished sterilized samples" were used for in vivo, ex vivo animal testing, biocompatibility, and mechanical testing. The data provenance is primarily through a series of standardized tests (ISO, USP, AAMI TIR). The source of the animal models for in vivo testing is not specified, but the human cells for hemolysis testing and canine for thrombogenicity testing are mentioned. It is implicitly a prospective study since testing was performed on the modified device to demonstrate performance.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
Not applicable. This is a medical device, and the "ground truth" for performance is established through adherence to engineering standards and physical/biological test results, not expert interpretation of data.
4. Adjudication Method for the Test Set
Not applicable. This is a medical device, and the "adjudication" is based on meeting predefined technical and biological specifications outlined in the referenced standards.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done as this is a medical device and not an AI-assisted diagnostic tool.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, the device performance was evaluated in a standalone manner through various functional, mechanical, and biocompatibility tests. There is no "human-in-the-loop" aspect to these performance assessments, as they measure the intrinsic properties and behavior of the device itself.
7. The Type of Ground Truth Used
The ground truth used for this device's acceptance is based on an objective assessment of physical and biological properties against established industry standards and regulatory guidance. This includes:
- Engineering standards compliance: ISO 11070 for mechanical tests.
- Biocompatibility standards compliance: ISO 10993 series and USP 33 <661>.
- Effectiveness of sterilization: AAMI TIR28:2001.
8. The Sample Size for the Training Set
Not applicable. This is a physical medical device, not an AI/algorithm-based system requiring a training set.
9. How the Ground Truth for the Training Set Was Established
Not applicable. As there is no training set, there is no ground truth established for one.
{0}------------------------------------------------
1 2010 SEP
:
510(k) Summary - K102176 4.0
| Submitter: | Medtronic CryoCath LP16771 Chemin Ste-MarieKirkland, QuebecH9H 5H3, CANADA |
|---|---|
| Contact Person: | Kari LahtiRegulatory Affairs Program ManagerTelephone: 763.526.1766Fax: 651.367.0575 |
| Date Prepared: | August 2, 2010 - Revised August 31, 2010 |
| Trade Name: | FlexCath® Steerable Sheath & Dilator |
| Classification: | Class IISteerable Catheter, 21 CFR § 870.1280 |
| Product Code: | DRA |
| Predicate Device(s): | The subject device is equivalent to the following devices:• K081049 - FlexCath Steerable Sheath & Dilator, Models3FC10, 3FC12 |
| Device Description: | The FlexCath Steerable Sheath is a deflectable catheter introducerused to facilitate placement of a catheter through the skin into theartery or vein.It is comprised of the following two (2) main sections: the shaft andthe handle.A dilator is included with each sheath.This application addresses changes to the 12F FlexCath sheath tipand valve assembly. |
| Intended Use: | The FlexCath Steerable Sheath is intended for percutaneouscatheter introduction into the vasculature and into the chambers ofthe heart. The sheath deflection facilitates catheter positioning. |
| Functional andSafety Testing: | To verify that the modified device design met its functional andperformance requirements, representative finished sterilizedsamples of the subject device underwent the following in vivo, exvivo animal testing, biocompatibility and mechanical testing inaccordance with applicable industry standards and FDA guidance.Testing included:• Hemostasis valve leak testing (per ISO 11070)• Hub-to shaft tensile (per ISO 11070) |
- Shaft leak testing (per ISO 11070)
.
:
{1}------------------------------------------------
- · Assessment of the force required to detach the dilator luer lock from the sheath valve cap
- · Force required to remove the dilator from the sheath
- · Tensile testing of bond joints (in addition to those required by ISO 11070) including:
- valve hub to valve cap o
- o hub body to extension
- tube bond and stopcock to extension tube joints o
- · Sheath tip robustness testing after multiple catheter deployments/retractions, both in bench and animal models
- · Air aspiration and flushing ability
- · Tip Strength
- · Deflection testing
- · Assessed impact of changes in relation to current sterilization cycle in accordance with AAMI TIR28:2001.
Biocompatibility Testing:
Biocompatibility of the modified hub material for the subject device included:
- · Physiochemical testing USP 33 <661>
- · Cytotoxicity testing per ISO 10993-5 (2009)
- Hemolysis testing (human activated and indirect) per ISO 10993-4 (2002 Amd 2006)
Leveraged biocompatibility of the predicate device included:
- · Kligman Maximization Test per ISO 10993-10 (2002)
- · Rabbit Pyrogen Test -- Material Meditated per ISO 10993-11 (2006)
- · Intracutaneous Test per ISO 10993-10 (2002)
- · Systemic Injection Test per ISO 10993-11 (2006)
- · Complement Activation Assay per ISO 10993-4 (2002)
{2}------------------------------------------------
- UPTT per ISO 10993-4 (2002) •
- · Thrombogenicity In vivo canine per ISO 10993-4 (2002)
The changes to the subject FlexCath Steerable Sheath do not affect · Conclusion: the intended use of the device, do not alter the fundamental scientific technology of the device, or raise new issues of safety or effectiveness. The FlexCath Steerable Sheath is therefore · substantially equivalent to the predicate FlexCath Steerable Sheath.
{3}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services USA. The logo features a stylized eagle with three overlapping wings, representing the department's mission to protect the health of all Americans. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Medtronic CyroCath LP c/o Ms. Kari Lahti Regulatory Affairs Program Manager 16771 Chemn St-Marie Kirkland, Quebec Canada H9H 5H3
SEP 1 2010
K102176 Re:
Trade/Device Name: FlexCath® Steerable Sheath & Dilator Common Name: Steerable Catheter Regulation Number: 21 CFR 870.1280 Regulatory Class: II Product Code: DRA Dated: August 2, 2010 Received: August 3, 2010
Dear Ms. Lahti:
We have reviewed your Section 510(k) premarket notification of intent to market the devices we nave reviewed your bection 510(x) premained is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use stated in the encrease) to tegans to the Medical Device Amendments, or to commerce prices that have been reclassified in accordance with the provisions of the Federal recomments (DMA) and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). and Cosment Act (Act) that to not require approvince to the general controls provisions of the Act. The Y ou may, merelore, market the devices of the more of the manual registration, listing of
general controls provisions of the Act include requirements for annual register and general controls provisions of the rice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability adulteration. Prease note. CDICT does not overance interesting must be truthful and not misleading.
{4}------------------------------------------------
Page 2 - Ms. Kari Lahti
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Zuckerman, M.D. Bram D Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
K102176
3.0 Indications for Use Statement
510(k) Number (if known): K_102176
Device Name: FlexCath® Steerable Sheath and Dilator
Indications for Use:
The FlexCath Steerable Sheath is intended for percutaneous catheter introduction into the vasculature and into the chambers of the heart. The Sheath deflection facilitates catheter positioning.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division of Cardiovascular Devices
510(k) Number K102176
§ 870.1280 Steerable catheter.
(a)
Identification. A steerable catheter is a catheter used for diagnostic and monitoring purposes whose movements are directed by a steering control unit.(b)
Classification. Class II (performance standards).